Doxortere 10mg Injection
Rx RequiredSalt Composition: Doxorubicin Hydrochloride Injection
Expiry Date: 01/2028
Buy at $9.80
Inclusive of all taxes
1
About The Product
Bladder Cancer , Breast Cancer
Description
Doxortere 10mg Injection is a allopathy based anticancer medication that is used to treat various cancers including blood cancers (leukemias, lymphomas, multiple myeloma), breast cancer, ovarian cancer, and others like lung, stomach, thyroid, sarcomas, and AIDS-related Kaposi's sarcoma.
Doxortere 10mg Injection contains conventional Doxorubicin Hydrochloride that damage DNA and cell membranes leading to cancer cell death.
Common Side Effects
- Like any other chemical based medication, Doxortere 10mg Injection also has certain common side effects.
- Consult your doctor, if side effects persist for longer period of time. ● Headache ● Cough ● Diarrhea ● Nausea ● Weakness ● Itchy skin or rash ● Shortness of breath ● Decreased appetite ● Infection in the nose or throat ● Fever ● Pain in your muscles, bones, and joints ● Heart problems ● Bone Marrow Supression ● Secondary Leukaemia Risk ● Severe Allergic Reactions
Dosage And Administration
- Doxortere 10mg Injection is administered intravenously (In Veins) by a doctor or an experienced nurse.
- It is advice not to self administer the injection on your own.
- For personalized dosage ask your doctor about the same.
- As Dosage is entirely based on the body surface area, type of cancer, its stage as well as patient's overall health.
Mechanism Of Action
Doxortere 10mg Injection contains Doxorubicin Hydrochloride that works by inhibiting the enzyme topoisomerase II, which is essential for DNA replication in cancer cells.
It also damages DNA and cell membranes leading to cancer cell death.
Safety Advice
Faqs
Doxortere 10mg Injection treats various cancers including blood cancers (leukemias, lymphomas, multiple myeloma), breast cancer, ovarian cancer, and others like lung, stomach, thyroid, sarcomas, and AIDS-related Kaposi's sarcoma.
References
• Rivankar, S. (2014).
An overview of doxorubicin formulations in cancer therapy. Journal of cancer research and therapeutics, 10(4), 853-858. • Carvalho, C., Santos, R.
X., Cardoso, S., Correia, S., Oliveira, P. J., Santos, M.
S., & Moreira, P. I.
(2009). Doxorubicin: the good, the bad and the ugly effect.
Current medicinal chemistry, 16(25), 3267-3285. • Cummings, J., Anderson, L., Willmott, N., & Smyth, J. F.
(1991). The molecular pharmacology of doxorubicin in vivo.
European Journal of Cancer and Clinical Oncology, 27(5), 532-535. • Tacar, O., Sriamornsak, P., & Dass, C. R.
(2013). Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems.
Journal of pharmacy and pharmacology, 65(2), 157-170.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
